(Times of Israel) Shoshanna Solomon - Israel's MediWound has received a contract for up to $43 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to adapt its lead product, a gel based on pineapple enzymes for the treatment of burns, to treat mustard gas injuries in case of a mass casualty event. MediWound's first product, NexoBrid, is the first approved pharmacological treatment for the removal of scab tissue that is associated with severe burns. The drug is considered a new method of burn care management, with an ability to non-surgically and rapidly remove dead or damaged tissue earlier and without harming viable tissue.
2018-09-28 00:00:00Full ArticleBACK Visit the Daily Alert Archive